ImmunoCellular Therapeutics FY14 results

• ImmunoCellular Therapeutics (OTCPK:IMUC -6.8%) FY14 results: Revenues: $0; R&D Expense: $6M (+13.2%); SG&A: $3.2M (-5.9%); Opearting Loss: ($9.9M) (-4.2%); Net Loss: ($9.4M) (-6.8%); Loss Per Share: ($0.16) (unch); Quick Assets: $23.2M (-15.9%).
• No guidance given.